San Diego biotech experiments with treatment for Parkinson's. Now it's going public.
Aspen Neuroscience, a San Diego biotech developing a therapy to replace brain cells lost to Parkinso... Aspen Neuroscience, a San Diego biotech, is planning an initial public offering for its lead candidate, sasineprocel, which aims to replace brain cells lost to Parkinson's disease. The company has been developing regenerative therapies since 2018 and plans to raise $150 million by offering 9.4 million shares at $15 to $17 each. The money would help fund the development of sasaneprocel. The therapy uses patient's own skin cells to reprogram them into stem cells and develop them into neuron precursors, which are then transplanted into the brain to replace lost dopamine-producing neurons. However, it is too early to know how well it works.
Publicados : 15 horas atrás por Noelle Harff, The San Diego Union-Tribune no Business Health
Aspen Neuroscience, a San Diego biotech developing a therapy to replace brain cells lost to Parkinson's disease, announced plans Monday for an initial public offering.
The company has been developing... [1506 symbols]
Tópicos: Biotech
